AC
VTGN icon

AlphaCore Capital’s VistaGen Therapeutics VTGN Stock Holding History

AlphaCore Capital’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-333
Closed -$12K – 174
2022
Q1 		$12K Buy
+333
New +$14.5K ﹤0.01% 117

Other funds holding VTGN

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AlphaCore Capital's VTGN Position: Q2 2022 in Review

AlphaCore Capital sold out of VistaGen Therapeutics (VTGN) in Q2 2022, closing a stake of 333 shares — an estimated $12K sold.

AlphaCore Capital first reported a position in VTGN in Q1 2022 and held it in 1 quarter. The position peaked at $12K in Q1 2022. 112 funds tracked by Wall St. Rank hold VTGN as of Q2 2022.

  • AlphaCore Capital reported no remaining VistaGen Therapeutics position as of Q2 2022 after selling out during the quarter.
  • AlphaCore Capital sold 333 VistaGen Therapeutics shares in Q2 2022, an estimated $12K.
  • AlphaCore Capital first reported a position in VistaGen Therapeutics in Q1 2022 and held it in 1 quarter.
  • AlphaCore Capital's VistaGen Therapeutics position peaked at $12K in Q1 2022.
  • 112 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2022.

Based on AlphaCore Capital's 13F filing for Q2 2022, filed 12 Aug 2022.